Plain-English translation of NCT07733115 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called QL1706 combined with two chemotherapy medications (gemcitabine and cisplatin) for people with advanced bile duct cancer. The study wants to see if this combination can shrink tumors and help people live longer. You would be one of 38 patients receiving this new treatment approach.
Bile duct cancer is aggressive and difficult to treat, and most patients haven't had good options for their first round of treatment. This medication may help by boosting the immune system to fight cancer cells more effectively when combined with chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of the new medication, gemcitabine, and cisplatin together every three weeks for up to 8 cycles (about 6 months). After that, you would continue receiving just the new medication alone as maintenance therapy until your cancer progresses or you experience serious side effects, which could last up to 2 years. You would have regular blood tests, imaging scans every 9 weeks, physical exams, and heart monitoring at each visit.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China